CLINICAL TRIALS PROFILE FOR GEMFIBROZIL
✉ Email this page to a colleague
All Clinical Trials for GEMFIBROZIL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000461 ↗ | Harvard Atherosclerosis Reversibility Project (HARP) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 1986-12-01 | To determine by sequential coronary arteriography whether a lipid-lowering diet with and without lipid-lowering drugs could reverse coronary artery disease in normocholesterolemic patients. Also, to test whether fish oil supplements could improve human coronary atherosclerosis. Finally, to determine the effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. At least three clinical trials were conducted. |
| NCT00004266 ↗ | Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes | Completed | Hennepin County Medical Center, Minneapolis | Phase 3 | 1993-08-01 | OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients. |
| NCT00004266 ↗ | Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 | 1993-08-01 | OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GEMFIBROZIL
Condition Name
Clinical Trial Locations for GEMFIBROZIL
Trials by Country
Clinical Trial Progress for GEMFIBROZIL
Clinical Trial Phase
Clinical Trial Sponsors for GEMFIBROZIL
Sponsor Name
